Jaguar Health
201 Mission Street Suite 2375
San Francisco
CA
94105
United States
Tel: 415-999-7092
Website: https://jaguar.health/
237 articles about Jaguar Health
-
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
4/22/2024
Jaguar planning to begin commercial launch of FDA-approved Gelclair prescription gel for oral mucositis in Q3 2024.
-
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
4/16/2024
Jaguar Health, Inc. today announced that it has signed an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group PLC.
-
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
4/9/2024
Jaguar Health, Inc. announced the voting results of the Company's Special Meeting of Stockholders held on April 9, 2024.
-
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
4/8/2024
Jaguar Health, Inc. today announced that on April 5, 2024 the Company received formal notice that the Listing Qualifications Staff of The Nasdaq Stock Market LLC has granted Jaguar an additional grace period, through August 13, 2024, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market.
-
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
4/2/2024
Jaguar Health, Inc. today announced that Massimo Radaelli, PhD, has been appointed President of Jaguar International.
-
Jaguar Health Reports 2023 Financial Results
4/1/2024
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2023.
-
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
3/27/2024
Jaguar Health, Inc. announced that the company will conduct an investor webcast on Monday, April 1, 2024 at 8:30 a.m. Eastern Standard Time to review fourth-quarter 2024 financials and provide corporate updates.
-
GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
3/20/2024
Jaguar Health, Inc. announced that it has signed a binding term sheet covering the exclusive license and commercialization agreement for Jaguar's novel plant-based, FDA-approved prescription drug crofelemer with Turkish specialty pharmaceutical company Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret, A.S.
-
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
2/23/2024
Jaguar Health, Inc. provided an update regarding the status of its listing with The Nasdaq Stock Market LLC.
-
Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
2/15/2024
Jaguar Health, Inc. announced that it has reached agreement with the U.S. Food and Drug Administration on the design and conduct of a clinical field study of Canalevia-CA1, the company's FDA conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea in dogs, for full approval of the product.
-
Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
2/14/2024
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company is donating a supply of its novel plant-based, FDA-approved prescription drug Mytesi to Direct Relief, a Santa Barbara, California-based humanitarian aid organization.
-
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
2/12/2024
Jaguar Health (NASDAQ:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) has submitted an Orphan Drug Designation (ODD) application to the U.S. Food and Drug Administration (FDA) for crofelemer.
-
Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference
1/29/2024
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on January 31, 2024 at The Microcap Conference in Atlantic City, New Jersey.
-
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
1/25/2024
Jaguar Health, Inc. announced that a dog study evaluating the effects of crofelemer in providing symptomatic relief of diarrhea associated with the irreversible pan-human epidermal growth factor receptor tyrosine kinase inhibitor neratinib has been published in the peer-reviewed journal PLOS ONE.
-
MASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family Company
12/7/2023
Napo Pharmaceuticals, a Jaguar Health, Inc. family company, announced that a Multinational Association of Supportive Care in Cancer webinar titled "GI Toxicities from Cancer Therapies - Prevention and Management," taking place Monday, January 29, 2024 from 11:30 AM to 12:30 PM Eastern Standard Time, was made possible by an unrestricted educational grant from Napo.
-
FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs
12/4/2023
Jaguar Health, Inc., under its Jaguar Animal Health tradename for the veterinary market, announced that the U.S. Food and Drug Administration has approved renewal of Canalevia-CA1.
-
Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference
11/30/2023
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on December 5, 2023 at the MedInvest Oncology Investor Conference.
-
Top Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming
11/21/2023
Napo Pharmaceuticals, a Jaguar Health, Inc. family company, announced that the company has not yet been provided with results from the company's GCP vendors supporting Napo's pivotal Phase 3 OnTarget trial.
-
Jaguar Health Reports Third Quarter 2023 Financial Results
11/14/2023
Jaguar Health, Inc. today reported consolidated third-quarter 2023 financial results and provided Company updates.
-
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - November 10, 2023
11/10/2023
Jaguar Health, Inc. announced that, effective November 7, 2023, the Company granted 7,500 restricted stock units to one new employee.